GÖTEBORG, Sweden, Dec. 1, 2021 /PRNewswire/ -- As announced on 30 November, 2021, Vitrolife AB (publ) completed the acquisition of Igenomix, as a result, changes will be made to the executive management team effective 1 January, 2022.
The executive management team will from 1 January, 2022, consist of:
Thomas Axelsson, President and Chief Executive Officer
Francisco Jiménez, SVP Strategy & Corporate Development
Karin Koritz Russberg, SVP HR & Sustainability
Carlos Simón, Chief Scientific Officer
Patrik Tolf, Chief Financial Officer
Claus Bisgaard, SVP Vitrolife Technology
Ricardo Capella, SVP Igenomix
Maria Forss, SVP Vitrolife Consumables
Rickard Ericsson, SVP Vitrolife Sales & Marketing
Francisco Rodriguez, SVP Igenomix Affiliates
Gothenburg, December 1, 2021
VITROLIFE AB (publ)
Thomas Axelsson, CEO
Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14
The information was submitted for publication, through the agency of the contact person set out above, at 1.00 pm CET on December 1, 2021.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content:
SOURCE Vitrolife AB (publ)